Literature DB >> 17569779

Complex regulation of pulmonary inflammation and fibrosis by CCL18.

Kerill Pochetuhen1, Irina G Luzina, Virginia Lockatell, Jung Choi, Nevins W Todd, Sergei P Atamas.   

Abstract

Elevated pulmonary levels of CCL18 have been associated with influx of T lymphocytes, collagen accumulation, and a decline in lung function in pulmonary fibrosis patients. We previously reported that overexpression of CCL18 in mouse lungs triggers selective infiltration of T lymphocytes and moderate lymphocyte-dependent collagen accumulation. We hypothesized that in combination with bleomycin injury, overexpression of CCL18 will worsen the severity of lung inflammation and fibrosis. Mice were infected with a replication-deficient adenovirus encoding CCL18 and then instilled with bleomycin; control mice were challenged with either CCL18 overexpression or bleomycin. Additive effects of CCL18 overexpression and bleomycin injury were observed on pulmonary inflammation, particularly on T-cell infiltration, and increased levels of tumor necrosis factor-alpha, interferon-gamma, matrix metalloproteinase (MMP)-2, and MMP-9. Despite the additive effect on inflammation, CCL18 overexpression unexpectedly attenuated the bleomycin-induced collagen accumulation. Pulmonary levels of active transforming growth factor-beta1 mirrored the changes in collagen levels. Depletion of T cells with antilymphocyte serum or pharmacological inhibition of MMPs with GM6001 abrogated accumulation of collagen and increases in the levels of tumor necrosis factor-alpha, interferon-gamma, and active transforming growth factor-beta1. Thus, CCL18-stimulated T-lymphocytic infiltration is by itself mildly profibrotic to a healthy lung, whereas it partially protects against lung fibrosis in an inflammatory profibrotic pulmonary milieu.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569779      PMCID: PMC1934523          DOI: 10.2353/ajpath.2007.061167

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

Review 1.  Alternative activation of macrophages.

Authors:  Siamon Gordon
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

2.  Effect of cytotoxic monoclonal antibody depletion of T-lymphocyte subpopulations on bleomycin-induced lung damage in C57BL/6J mice.

Authors:  D Janick-Buckner; G E Ranges; M P Hacker
Journal:  Toxicol Appl Pharmacol       Date:  1989-09-15       Impact factor: 4.219

3.  Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs.

Authors:  Philippe Bonniaud; Gail Martin; Peter J Margetts; Kjetil Ask; Jennifer Robertson; Jack Gauldie; Martin Kolb
Journal:  Am J Respir Cell Mol Biol       Date:  2004-07-15       Impact factor: 6.914

Review 4.  Cytokine regulation of pulmonary fibrosis in scleroderma.

Authors:  Sergei P Atamas; Barbara White
Journal:  Cytokine Growth Factor Rev       Date:  2003-12       Impact factor: 7.638

Review 5.  Matrix metalloproteinase-9 in lung remodeling.

Authors:  Jeffrey J Atkinson; Robert M Senior
Journal:  Am J Respir Cell Mol Biol       Date:  2003-01       Impact factor: 6.914

6.  Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis.

Authors:  Francois Huaux; Tianju Liu; Bridget McGarry; Matt Ullenbruch; Zhou Xing; Sem H Phan
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

7.  Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta.

Authors:  Masaki Fujita; John M Shannon; Osamu Morikawa; Jack Gauldie; Nobuyuki Hara; Robert J Mason
Journal:  Am J Respir Cell Mol Biol       Date:  2003-06-19       Impact factor: 6.914

8.  Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts.

Authors:  Sergei P Atamas; Irina G Luzina; Jung Choi; Natalya Tsymbalyuk; Nicholas H Carbonetti; Ishwar S Singh; Maria Trojanowska; Sergio A Jimenez; Barbara White
Journal:  Am J Respir Cell Mol Biol       Date:  2003-06-12       Impact factor: 6.914

9.  Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients.

Authors:  Irina G Luzina; Sergei P Atamas; Robert Wise; Fredrick M Wigley; Jung Choi; Hui Qing Xiao; Barbara White
Journal:  Arthritis Rheum       Date:  2003-08

10.  T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis.

Authors:  Zhenyue Hao; Brigitte Hampel; Hideo Yagita; Klaus Rajewsky
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

View more
  31 in total

1.  CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma.

Authors:  Zeyu Lin; Wenbin Li; Heyun Zhang; Wei Wu; Yaorong Peng; Yunjie Zeng; Yunle Wan; Jie Wang; Nengtai Ouyang
Journal:  Tumour Biol       Date:  2015-10-08

Review 2.  Functional autoantibodies in systemic sclerosis.

Authors:  Jeannine Günther; Judith Rademacher; Jakob M van Laar; Elise Siegert; Gabriela Riemekasten
Journal:  Semin Immunopathol       Date:  2015-08-21       Impact factor: 9.623

3.  Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.

Authors:  Daniel J Kass; Guoying Yu; Katrina S Loh; Asaf Savir; Alain Borczuk; Rehan Kahloon; Brenda Juan-Guardela; Giuseppe Deiuliis; John Tedrow; Jiin Choi; Thomas Richards; Naftali Kaminski; Steven M Greenberg
Journal:  Am J Pathol       Date:  2012-03-16       Impact factor: 4.307

4.  ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin.

Authors:  Michael E Powers; Hwan Keun Kim; Yang Wang; Juliane Bubeck Wardenburg
Journal:  J Infect Dis       Date:  2012-04-02       Impact factor: 5.226

5.  IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism.

Authors:  Pavel Kopach; Virginia Lockatell; Edward M Pickering; Ronald E Haskell; Richard D Anderson; Jeffrey D Hasday; Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

6.  Interleukin-33 potentiates bleomycin-induced lung injury.

Authors:  Irina G Luzina; Pavel Kopach; Virginia Lockatell; Phillip H Kang; Ashish Nagarsekar; Allen P Burke; Jeffrey D Hasday; Nevins W Todd; Sergei P Atamas
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

7.  Transcriptomic evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis.

Authors:  Irina G Luzina; Mariah V Salcedo; Mónica L Rojas-Peña; Anne E Wyman; Jeffrey R Galvin; Ashutosh Sachdeva; Andrew Clerman; June Kim; Teri J Franks; Edward J Britt; Jeffrey D Hasday; Si M Pham; Allen P Burke; Nevins W Todd; Sergei P Atamas
Journal:  Cell Immunol       Date:  2018-01-03       Impact factor: 4.868

8.  Segmental allergen challenge enhances chitinase activity and levels of CCL18 in mild atopic asthma.

Authors:  M L Gavala; E A B Kelly; S Esnault; S Kukreja; M D Evans; P J Bertics; G L Chupp; N N Jarjour
Journal:  Clin Exp Allergy       Date:  2013-02       Impact factor: 5.018

9.  Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes.

Authors:  Irina G Luzina; Nevins W Todd; Natalia Nacu; Virginia Lockatell; Jung Choi; Laura K Hummers; Sergei P Atamas
Journal:  Arthritis Rheum       Date:  2009-05

10.  Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis.

Authors:  Irina G Luzina; Virginia Lockatell; Sang W Hyun; Pavel Kopach; Phillip H Kang; Zahid Noor; Anguo Liu; Erik P Lillehoj; Chunsik Lee; Alba Miranda-Ribera; Nevins W Todd; Simeon E Goldblum; Sergei P Atamas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-03-18       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.